BUSINESS

(Update) Japan Approves Novartis’ SMA Gene Therapy Zolgensma; 15-20 Patients Expected Annually

March 19, 2020
Japan’s health ministry approved Novartis’ spinal muscular atrophy (SMA) gene therapy Zolgensma on March 19 for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at diagnosis, the Swiss giant said. The official…

To read the full story

Related Article

BUSINESS

By Yoshinori Sagehashi

The government is in the process of finalizing the 2021 Basic Policy for Economic and Fiscal Management and Reform (honebuto). This year’s policy will have a higher importance than previous ones because the drastic reforms of the drug pricing system…

By Eric Persoff

Last month, when discussing how life science manufacturers should react to the evolving pricing environment in Japan, I wrote about how manufacturers should align with stakeholders in government and the medical community on fair compensation for innovative, value creating, biopharmaceutical…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…